Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present opinion among 11 TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price goal of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.

From the newest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The retail or Long Term Care segment has selling of prescription medications as well as assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as related services, which includes medical, pharmacy, dental, behavioural health, medical relief abilities. The Corporate segment involves in providing administrative services and management. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.